Glucose Control Okay With Novel Thrice-Weekly Insulin, Mount Sinai Hospital Study

Published: Mar 10, 2011

MedPageToday -- A novel insulin that releases over several days appears as effective as once-daily standard insulin in type 2 diabetes, an open-label trial found. Glycosylated hemoglobin levels reached a similar 7.2% to 7.5% over 16 weeks whether patients got the novel insulin degludec three times a week or once daily, or standard insulin glargine (Lantus) once daily, Bernard Zinman, MD, of Mount Sinai Hospital at the University of Toronto, and colleagues reported online in The Lancet.

Back to news